Introduction
Biomarker discovery efforts in recent years have been aided by the emergence of microarrays, whereby the expression level of thousands of genes is assayed in one experiment (DeRisi et al., 1996; Schena et al., 1996; Marton et al., 1998; Duggan et al., 1999) . Utilizing this technology, expression profiles that correspond to in vitro drug treatment (van Lint et al., 1996; He et al., 2001; Ragione et al., 2001; Fleming et al., 2002; Clarke et al., 2003; Glaser et al., 2003) , tumor classification (Golub et al., 1999; Ramaswamy et al., 2001; Devilard et al., 2002; Hedenfalk et al., 2003) or prognosis van't Veer et al., 2002; Nutt et al., 2003) can be identified. This approach can be applied to preclinical as well as clinical samples, thus allowing biomarker identification and validation in animal models prior to initiation of clinical testing. While accessible surrogate tissues such as buccal mucosa, skin, blood and plasma are very useful for biomarker analysis (Adjei et al., 2000; Albanell et al., 2002; Clarke et al., 2003; DePrimo et al., 2003; O'Farrell et al., 2003) , tumor tissue, when available, provides a direct readout of drug activity on the target tissue. Preclinical xenograft tumor models are readily amenable to such analyses (Laird et al., 2002; Mendel et al., 2003; Zembutsu et al., 2003) , and tumor biopsies from clinical trials are becoming increasingly available, under appropriate informed consent guidelines.
Agents targeting tyrosine kinases are among the most advanced of the molecular targeted therapeutics being developed in oncology. Targets including HER2, BcrAbl, epidermal growth factor receptor (EGFR) and vascular endothelial growth factor receptor (VEGFR) are well validated for their roles in oncogenesis, and drugs affecting these kinases (i.e. Herceptin, Gleevec, Iressa, Avastin) are either approved or in advanced clinical testing (Slamon and Pegram, 2001; Druker, 2002; Ferrara, 2002; Herbst, 2002) . SU11248, currently in Phase II clinical studies, is a multitargeted, small molecule receptor tyrosine kinase (RTK) inhibitor with activity against the split kinase domain RTKs, PDGFR, VEGFR, KIT and FLT3. In vitro, SU11248 inhibits these targets in biochemical, ligand-dependent phosphorylation and cell proliferation assays with IC 50 values in the low nanomolar range . In vivo, SU11248 induces growth inhibition, stasis or regression of large established tumors, depending on the xenograft model investigated. For example, SU11248 induces regression of Colo205 colon tumors, while C6 rat glioma tumors are growth inhibited.
Consistent with its antiproliferative activity against VEGF-stimulated human umbilical vascular endothelial cells (HUVECs), SU11248 also exhibits antiangiogenic activity in vivo: treatment of mice bearing C6 glioma xenografts results in decreased tumor microvessel density .
Building on the knowledge of SU11248 efficacy in several in vivo models, gene expression profiling was initiated to identify clinically translatable biomarkers of SU11248 activity to ultimately aid development of the drug. We report here the results of this study, in which several genes that change in abundance in response to SU11248 were identified using microarrays and quantitative reverse-transcription polymerase chain reaction (qRT-PCR). Subsequent to gene expression analysis, cadherin-11 protein level was also found to be upregulated in xenograft tumors after mice were treated with SU11248. Similar to the results observed in preclinical xenograft tumors, SU11248 treatment also resulted in an increased level of cadherin-11 protein in a subset of tumor biopsies after patients were treated with SU11248. These results suggest the strategy of utilizing gene expression profiling of preclinical models to identify candidate biomarkers of drug action, such as cadherin-11, is feasible and should be further evaluated and translated to a clinical setting.
Results

SU11248 induces gene expression changes in xenograft tumors
As previously reported, SU11248 regresses large established Colo205 xenograft tumors when administered daily at 40 mg/kg . The antitumor activity of SU11248 on this model appears to be mediated through inhibition of the VEGF and PDGF receptor targets expressed on the endothelium and/or stroma (Sundberg et al., 1993; Fukumura et al., 1998; Ferrara et al., 1999; Mendel et al., 2003; Potapova et al., 2003) as Colo205 cells do not detectably express receptor tyrosine kinases (RTKs) targeted by SU11248 (G Li, personal communication). To identify biomarkers reflecting SU11248 in vivo activity, mice bearing Colo205 xenograft tumors were given a single dose of vehicle or 40 mg/kg SU11248, a dose sufficient for in vivo target inhibition or for efficacy when administered daily . Two tumors were isolated from each treatment group at 6 and 24 h post-treatment for microarray analysis.
To identify gene expression induced by SU11248 treatment, Affymetrix U95A arrays, with sequences representing over 10 000 genes, were used. Probe sets with a signal intensity resulting in an absolute call of 'present' by Microarray Suite software were deemed expressed (see Materials and methods for details). Using this criterion, vehicle-treated tumors expressed a mean of 5489761 and 57397257 genes at 6 and 24 h, respectively. SU11248-treated tumors expressed a mean of 56357578 and 5872720 genes at 6 and 24 h, respectively. Therefore, on a global level, the number of genes detected did not significantly differ (P ¼ 0.53; unpaired, two-tailed t-test) between vehicle-(mean of 5754 transcripts) and SU11248-treated tumors (mean of 5614 transcripts) at the time points examined. In addition, approximately 5000 transcripts were commonly expressed in all tumors isolated 6 and 24 h posttreatment in both treatment groups.
Hierarchical clustering combined with statistical analysis of expression patterns of all tumors identified 194 differentially expressed genes (approximately 4% of all genes detected) in SU11248 compared to vehicletreated tumors (Figure 1a ; t-test, Po0.05; see Materials and methods for details). The heat map illustrates the similarities of the SU11248-treated tumors as compared to the vehicle-treated tumors. The dendrogram indicates that duplicate vehicle-treated tumors form an independent cluster at each time point of treatment, illustrating the kinetics of the gene expression patterns. In addition, two SU11248-treated tumors (isolated 24 h post-treatment) also form an independent cluster. However, one of the drug-treated tumors (isolated 6 h post-treatment) was most similar to a SU11248-treated tumor isolated at the 24 h time point. These data indicate that whereas the majority of replicate tumors examined are most similar to each other, some gene expression differences do occur.
A similar analysis was performed to identify gene expression alterations in tumors at each point post drug treatment. At the 6 h time point, 320 genes were differentially expressed (t-test, Po0.05) when gene expression profiles from vehicle-treated tumors were compared to SU11248-treated tumors. At 24 h after treatment, 391 genes were differentially expressed (t-test, Po0.05) in SU11248 versus vehicle-treated tumors (data not shown). In addition, four genes were similarly upregulated by SU11248 at both time points (Figure1b; t-test, Po0.05) and 6 genes were commonly downregulated by SU11248 in both xenograft tumors at both time points examined (Figure 1c ; t-test, Po0.05).
To identify SU11248-induced alterations that might be more amenable to translation to clinical studies, we looked for robust changes in gene levels. Using a cutoff of genes that changed in abundance by 1.7-fold or more after drug treatment and were called present by Microarray Suite (see Materials and methods for details), over 100 transcripts were identified (Table 1;  see supplementary Table 4 for a complete list). The majority of identified genes have putative roles in proliferation, transcription, cell-cycle control, metabolism, adhesion or protein regulation/transport. In addition, some genes identified by hierarchical clustering/t-test analysis as significantly regulated by SU11248 treatment (Table 1 and Figure 1a ) also fulfilled the aforementioned data filter criteria.
Taqman confirmation of SU11248-regulated transcripts
A subset of the SU11248-regulated transcripts were chosen for confirmatory TaqMan analysis (Table 2 and 3), which provides a robust, quantitative assessment of gene expression. Genes were chosen based on putative roles in cellular processes that might be regulated by a molecular targeted agent such as SU11248 (e.g. proliferation and/or apoptosis) and/or availability of immunohistochemical (IHC) reagents for detection of protein product. This analysis demonstrated that amphiregulin, cyclin C, cadherin-11, phosphoinositol 3-kinase p85 subunit and EphB4 (gene products involved in intercellular interactions and signaling) were upregulated in tumors in response to SU11248 treatment. Genes such as cdk2, OB-cadherin 2 and mucin 1 (gene products involved in adhesion and cell-cycle regulation) were downregulated in response to SU11248 treatment (Table 3 ). In addition, only four of the nine genes examined had similar patterns of regulation by microarray and TaqMan analysis; these were amphiregulin, cyclin C, OB-cadherin 2 and VHL. These results highlight the importance of a quantitative, sensitive method such as TaqMan to validate gene expression changes observed in microarray experiments after a manageable number of transcripts are identified via array analysis.
Cadherin-11 protein expression is regulated by SU11248
Although only B50% of the genes exhibited a similar profile when comparing microarray and TaqMan data, the quantitative nature of TaqMan suggested that the gene expression changes detected using this technology (Table 3) are bona fide. We therefore wanted to determine if the SU11248-induced gene expression changes detected by TaqMan analysis (Table 3) would also be observed at the protein level. Markers that exhibited the most robust gene expression changes (i.e. cyclin C and cadherin-11) via TaqMan were chosen for subsequent protein analysis. Colo205 xenografts were treated with a single dose of 40 mg/kg SU11248 and tumors were isolated 24 and 48 h post-treatment. These time points were chosen based on the assumption that upregulation of cyclin C or cadherin-11 protein would be delayed as compared to the observed upregulation of gene levels.
In sections from tumors treated with 40 mg/kg SU11248, the number of cells positive for membranelocalized cadherin-11 increased at 48 h in drug-treated (4474.1%; n ¼ 3 tumors) as compared to vehicle-treated tumors (0.971.6%; n ¼ 3 tumors; Figure 2a ) and was significant (P ¼ 0.025, unpaired, two-tailed t-test). In addition, the overall intensity of cadherin-11 protein expression appeared to increase. Although upregulation Figure 1 Hierarchical clustering analysis of SU11248-induced gene expression. Hierarchical clustering analysis and heat map representation of (a) 194 genes that differ in expression between vehicle-and SU11248-treated tumors (t-test, Po0.05; see supplementary Table 4 for a complete list of gene names). (b) Genes similarly upregulated or (c) downregulated by SU11248 at 6 and 24 h time points. Genes listed are: AF000652, syntenin; M81118, alcohol dehydrogenase 5; AI885852, clone with homology to histone H2A; AB018280, KIAA0737; AC004381, BAC clone CIT987SK-44M2; L05424, hyaluronate receptor; D78586, carbamoylphosphate synthetase-aspartate transcarbamoylase-dihydroorotase; AB023210, KIAA0993; X66899, Ewing's sarcoma protein; U66615, BRG1 associated factor 155. Red refers to upregulation and green refers to downregulation of gene expression of cadherin-11 gene expression was observed at 24 h (Table 3) , the number of cells expressing membranelocalized cadherin-11 did not appear to differ in drug-as compared to vehicle-treated tumors 24 h after treatment (n ¼ 3 tumors per treatment group; data not shown).
Therefore, the results indicate that while kinetics of regulation of cadherin-11 gene and protein product differ, both transcript and protein product levels are upregulated by SU11248 treatment. In contrast to the results with cadherin-11, we were unable to find reagents 
Cadherin-11 is expressed in human tumors
As cadherin-11 protein expression in tumors has been reported only in neuroblastoma and prostate tumors (Shimono et al., 2000; Tomita et al., 2000) , the general applicability of cadherin-11 as a clinical biomarker in various types of solid tumors was unclear. We therefore analysed cadherin-11 expression in archived human tumors of the breast, colon, skin, kidney and thyroid by IHC. Tumors from two different individuals were examined in each case except thyroid, where two follicular and two papillary thyroid tumors (from four different individuals) were examined. Overall, membrane-localized cadherin-11 expression was detected in tumor cells in nine of the 12 tumors examined. Strong expression was detected in follicular thyroid (Figure 2b , left panel), invasive breast carcinoma (Figure 2b , right panel), papillary thyroid and renal tumor cells (data not shown) in both tumors of each type examined. Cadherin-11 expression was also detected in tumor cells of one of the two melanoma tumors examined (data not shown). In addition, cadherin-11 expression was localized to cell membranes, similar to that seen in Colo205 tumor xenografts. Cadherin-11 expression was not detected in colon adenocarcinoma cells, but was readily detected in adjacent normal skin present in both of the melanoma tumor samples (data not shown). As preclinical results identified upregulation of cadherin-11 expression in response to SU11248 treatment, it was unclear whether the lack of baseline expression in melanoma and colon tumors signified more or less promise for this potential biomarker in these tumor types. However, the data did indicate that the evaluation of cadherin-11 as a clinical biomarker of SU11248 activity was technically feasible in breast, thyroid, melanoma and renal tumors based on the detection of cadherin-11 expression in these tumor types. We next examined whether the level of cadherin-11 protein in tumor biopsies was altered after patients received SU11248. Serial biopsies were available from seven patients enrolled in a clinical trial involving SU11248 (Toner et al., 2003) . Cadherin-11 expression in tumor biopsies before and after 29 days of daily treatment with 50 mg of SU11248 was examined by IHC. All examined biopsies had readily detectable baseline expression of cadherin-11 in tumor cells. Tumors from three of the seven patients examined had an increased number of tumor cells with cadherin-11 membrane expression after SU11248 treatment ( Figure  3b , d, f) as compared to before treatment (Figure 3a , c, e). Biopsies exhibiting increased cadherin-11 expression were isolated from a breast carcinoma (Figure 3a, b) , follicular thyroid carcinoma (Figure 3c, d ) and a melanoma (Figure 3e, f) . In contrast, biopsies from a papillary thyroid, colon carcinoma, renal and a melanoma tumor did not demonstrate any apparent alteration in the expression of cadherin-11 (data not shown). Cadherin-11 expression was also consistently detected in fibroblasts, consistent with previous analyses of cadherin-11 expression in prostate (Tomita et al., 2000) and stomach (Shibata et al., 1996) tumors. In addition, cadherin-11 expression was detected in occasional pericytes and endothelium. However, cadherin-11 expression in these stromal components did not appear to alter after SU11248 treatment (AMM, unpublished observations).
Discussion
We have utilized gene expression profiling to identify molecular markers of the small molecule RTK inhibitor, SU11248, which is currently in Phase II clinical trials. Using xenograft tumors, numerous transcript biomar- kers of SU11248 in vivo activity were identified using microarrays and TaqMan. In addition, one of these markers, cadherin-11, was also found to have an increased level of protein in xenograft tumors in response to SU11248 treatment. Importantly, treatment with SU11248 also resulted in upregulation of cadherin-11 protein level in a subset of patient biopsies, recapitulating the preclinical results. Together these data demonstrate the feasibility of utilizing preclinical models combined with gene expression profiling to identify clinically translatable biomarkers of targeted therapeutics.
The putative function of a number of the identified SU11248-regulated genes is consistent with previously observed biological effects induced by SU11248. For instance, SU11248 elicited a decrease in microvessel density in a dose-and time-dependent manner in multiple xenograft models including Colo205 xenograft tumors (AD Laird, personal communication). Reduced microvessel density could lead to a hypoxic response in the tumor, consistent with observed upregulation of VEGF and c-jun genes (Table 1) , which are regulated by hypoxia (Bae et al., 1998; Semenza, 2000; Koong et al., 2000; Sonna et al., 2003) . In addition, treatment of mice with SU6668, a small molecule inhibitor of Flk-1/KDR, PDGFR and FGFR, induced apoptosis of tumor microvessels, and similarly resulted in upregulation of VEGF gene expression in Colo205 xenograft tumors (Laird et al., 2002) .
SU11248 treatment also resulted in increased levels of TC-PTP and BTF3, genes involved in apoptosis (Brockstedt et al., 1999; Gupta et al., 2002) . Regulation of these markers is also consistent with the previously observed dose-dependent induction of apoptosis in xenograft models by SU11248 Potapova et al., 2003) . These findings are consistent with a number of genes identified in this study representing molecular markers of SU11248 activity and suggest that modulation of these biomarkers also reflects the mechanism of action of this drug.
In comparing gene expression data from microarrays versus TaqMan, our confirmation rate of 50% was low. Although microarrays can provide a simultaneous analysis of over 10 000 transcripts, they are not as quantitative as methods such as TaqMan. The use of multiple arrays for each sample of interest and greater than two biological replicates (the number used in this study), although costly, might lead to better concurrence of data from these technologies. Our results suggest that confirmatory studies of array data should involve additional methods such as quantitative PCR.
TaqMan analysis also identified SU11248 induction of cadherin-11 gene expression in Colo205 xenograft tumors. Cadherin-11 gene levels were similarly upregulated in rat C6 glioma xenograft tumors in response to SU11248 treatment (data not shown), indicating that cadherin-11 is a biomarker for SU11248 activity in at least two xenograft tumor models. Interestingly, two forms (wild-type and a splice variant) of cadherin-11 have been detected (Okazaki et al., 1994; Kawaguchi et al., 1999) . Affymetrix array probes (and the TaqMan probes designed based on sequences on the array) do not distinguish wild-type from variant cadherin-11 (see Materials and methods; Table 2 ); therefore, it is unclear whether one or both forms of cadherin-11 are regulated at the gene level. However, upregulation of protein level was detected using an antibody specific for wild-type cadherin-11 (see Materials and methods; Okazaki et al., 1994; Kawaguchi et al., 1999) indicating that the level of wild-type cadherin-11 protein in tumor xenografts is affected by SU11248 treatment.
Importantly, upregulation of cadherin-11 protein level was also detected in human biopsies after SU11248 treatment. All analysed biopsies were from patients who received the same dosage of SU11248 (Toner et al., 2003) ; therefore, the changes in cadherin-11 levels do not appear to relate directly to the administered dose. However, studies are currently in progress to address whether changes in cadherin-11 levels correlate with pharmacokinetic parameters of SU11248 at the individual patient level.
Interestingly, human colon xenograft tumors were used as a model resulting in identification of cadherin-11 as a biomarker of SU11248 activity; however, the human colon tumor biopsy examined did not have detectable upregulation of cadherin-11 levels. In contrast, post-treatment biopsies from breast, thyroid and melanoma tumors exhibited upregulation of wild-type Figure 3 Immunohistochemical analysis of cadherin-11 expression in human tumor biopsies. Cadherin-11 expression before (a, c, e) and after (b, d, f) SU11248 treatment. Biopsies were from breast carcinoma (a, b), follicular thyroid carcinoma (c, d) and melanoma (e, f). Biopsies were taken before and after 29 days of treatment with SU11248. Images were taken at a magnification of Â 1000 cadherin-11 protein. These data suggest that the colon xenograft model used and the human colon tumor examined do not respond similarly to SU11248 and/or that a subset of human colon tumors might upregulate cadherin-11 levels in response to SU11248 treatment.
It is unknown why SU11248 treatment resulted in upregulation of cadherin-11 gene and protein level in xenograft tumors. Expression of cadherin-11, originally identified in osteoblasts (Okazaki et al., 1994) , is regulated by dexamethasone and TGFa in differentiating cells (Lecanda et al., 2000; Zhou and Skalli, 2000) but how inhibition of VEGFR and PDGFR by SU11248 affects the expression of cadherin-11 is unknown. Functionally, expression of wild-type cadherin-11 increases the adhesive nature and decreases the invasive capacity of SKBR3 breast tumor cells (Feltes et al., 2002) . In addition, expression of wild-type cadherin-11 decreases in vitro cell migration as well as pulmonary metastasis of mouse osteosarcoma cells (Kashima et al., 2003) . Therefore, SU11248-induced upregulation of cadherin-11 levels might alter the adhesive nature of treated tumor cells.
As treatment of xenograft models with efficacious doses of SU11248 has been demonstrated to reduce microvessel density, which is thought to be indicative of antiangiogenic activity , the observed increase in cadherin-11 expression might reflect a hypoxic response by the tumor. Expanded clinical biomarker studies involving SU11248 would benefit from a coordinated expression analysis of cadherin-11 and hypoxia markers such as HIF-1a to better understand the mechanism of regulation of this biomarker. As all tumor biopsies examined had baseline expression of cadherin-11, pre-existing cadherin-11 expression does not appear to predict whether SU11248 treatment will result in increased levels of this biomarker. However, Schueneman et al. (2003) have recently demonstrated modulation of PDGFR phosphorylation in xenograft tumor stroma after efficacious treatment with SU11248. Therefore, it would be interesting in future clinical biomarker studies to examine cadherin-11 and phospho-PDGFR expression in parallel to further address the relationship of PDGFR activity and change in cadherin-11 expression levels and determine if the baseline or post-treatment levels of phosphorylated PDGFR and VEGFR might correlate with changes in cadherin-11 levels after SU11248 treatment.
In summary, molecular markers of SU11248 in vivo activity were identified that are consistent with the mechanism of action of this drug. Importantly, protein levels of one of these markers, cadherin-11, were affected in preclinical xenograft tumors as well as human tumor biopsies by SU11248 treatment. These results indicate that the potential of this marker to demonstrate the biological activity of SU11248 on tumors can be evaluated at both the RNA and protein levels in clinical samples and suggest that wild-type cadherin-11 expression should continue to be examined in a clinical setting. Such biomarker studies are incorporated into current Phase II clinical trials involving SU11248 to assess efficacy and whether molecular markers such as wild-type cadherin-11 are biomarkers of biological activity and/or efficacy.
Materials and methods
In vivo animal studies
All procedures were conducted in accordance with Institutional Animal Care and Use Committee guidelines in the SUGEN Animal Facility, which is accredited by the Association for Assessment and Accreditation of Laboratory Animal Care International. Female athymic nu/nu mice (8-12 weeks old; Charles River, Hollister, CA, USA) were maintained under clean-room conditions in filter-top cages with Aspen Chip bedding housed on HEPA-filtered ventilated racks. Animal experiments were conducted as previously described (Laird et al., 2002) .
Colo205 (human colon) or C6 (rat glioma) cells were maintained and cultured as described (Laird et al., 2002; Mendel et al., 2003) . Tumor cells (5 Â 10 6 ) were implanted subcutaneously into the hind flank region of mice on day 0. Animals were treated by oral administration with citratebuffered solution (pH 3.5) or a single dose of 40 mg/kg SU11248 when tumors were 200-300 mm 3 in size. Tumors were snap frozen for RNA extraction or fixed in Strek Tissue Fixative (Strek Laboratories, La Vista, NE, USA). Tumors used in Affymetrix array analysis and IHC studies were isolated from two independent in vivo studies.
Gene expression profiling
Total RNA was prepared using the Nucleospin RNA Kit (Clontech, Palo Alto, CA, USA). RNA processing and hybridization protocols were carried out as recommended by Affymetrix (Santa Clara, CA, USA).
Analysis of gene expression profiling data
Data files were generated using Microarray Suite (Affymetrix, Santa Clara, CA, USA). Key parameters are average difference (AD), a relative indicator of transcript expression, and absolute call (AC), which indicates the presence or absence of each transcript. Transcripts with a present (AC) in all tumors in both treatment groups were used for analysis. For comparisons between different treatments, data were analysed using Access (Microsoft, Redmond, WA, USA) to identify transcripts present (AC) and a fold change X1.7 (increasing or decreasing) of AD values. Using duplicate control samples, a data requirement that all transcripts are present (AC) and exhibit at least a 1.7-fold change, was found to result in a reproducibility of 80% of probe sets (data not shown).
Statistical and hierarchical clustering
AD values were normalized using Z score transformation (Spotfire DecisionSite; Spotfire, Somerville, MA, USA; Cheadle et al., 2003) . To determine significant changes in gene expression, a two-tailed t-test comparing profiles from tumors treated with SU11248 versus vehicle was performed. Transcripts called present (AC) with positive AD values were considered, and those that differed (Po0.05) were identified. These transcripts were then analysed using hierarchical clustering to group genes according to similarities in expression (Spotfire DecisionSite).
Taqman analysis
Primers and probes were designed using Primer Express (Applied Biosystems, Foster City, CA, USA) and sequences represented by the Affymetrix probe set. Probes were labeled with reporter dye, 6-carboxy-fluorescein phosphoamidite (FAM), at the 5 0 end and dye quencher, minor groove binder (MGB), at the 3 0 end. Each 25-ml reaction consisted of 500 nM forward and reverse primer, 100 nM of TaqMan probe, cDNA (20 ng of total RNA) and TaqMan s One-Step RT-PCR Master Mix (Applied Biosystems). Thermal cycler conditions are as follows: 481C for 30 min, 951C for 10 min, 951C for 15 s followed by 601C for 1 min for 40 cycles, and 251C for 2 min. 18S ribosomal gene primer and probe pairs were purchased from Applied Biosystems.
Relative expression of specific transcripts was determined by the following calculation, as described in the Applied Biosystems users bulletin, 'Relative Quantitation of Gene Expression': relative expression ¼ 2
ÀDDCt
where DDCt ¼ ðCt target À Ct 18s control Þ drug treatment À ðCt target À Ct 18s control Þ vehicle treatment :
Antibodies
An antibody recognizing the cytoplasmic tail region of wildtype cadherin-11, which is distinct from the cytoplasmic tail of variant cadherin-11 (Okazaki et al., 1994; Kawaguchi et al., 1999) , was used (#71-760, Zymed Laboratories, Inc., South San Francisco, CA, USA).
Tissue samples -human tumors
All human tumors were obtained using IRB-approved written informed consent and were fixed in formalin and embedded in paraffin. Archived tumor samples ( Figure 2b) were from the SUGEN Tissue Bank. Tumors of the breast, colon, skin, kidney and thyroid were examined. Two tumors of each tissue type and two follicular and two papillary thyroid tumors were used. Biopsies ( Figure 3 ) were obtained from a clinical trial involving SU11248 (Toner et al., 2003) . Biopsies were obtained before and after 29 days after daily treatment with 50 mg of SU11248. Two pathologists prospectively documented pathology data.
Tissue samples -xenograft tumors
Tumors used in IHC analyses were isolated and placed in Strek tissue fixative (Strek Laboratories, La Vista, NE, USA) and embedded in paraffin. Membrane expression of wild-type cadherin-11 was evaluated (in a blinded manner) using images from three xenograft tumors/time point (four fields/tumor) at a magnification of Â 1000. Number of cells positive for membrane expression of wild-type cadherin-11 was calculated based on a percentage of total cells counted. An average of 82 cells was scored from each field.
Immunohistochemistry
Human and xenograft tumor sections (4 mm) were stained using an automated system (Ventana Medical Systems, Inc., Tucson, AZ, USA). In brief, slides were deparaffinized using heat at 751C and EZ Prep solution (#950-102, Ventana). Antigen retrieval was performed by incubating the slides for 30 min with CC2 (#950-123, Ventana), a citrate-based solution with pH 6.0. Primary antibody (5 mg/ml) was incubated for 24 min at room temperature, followed by 2.4 mg/ml biotinylated anti-rabbit secondary antibody (BA-1000, Vector Laboratories, Burlingame, CA, USA) with an incubation time of 8 min. Streptavadin-horereadish peroxidase with 3,3 0 diaminobenzidine as a substrate were used in conjunction with the secondary detection system. For xenograft studies, all tumors were also stained with the omission of primary antibody as a negative control.
Abbreviations HUVEC, human umbilical vascular endothelial cells; RTK, receptor tyrosine kinase; IHC, immunohistochemistry; qRT-PCR, quantitative reverse-transcription polymerase chain reaction.
